• Mashup Score: 10

    Significant advances in breast cancer (BC) treatment have been made in the last decade, including the use of immunotherapy and, in particular, immune checkpoint inhibitors that have been shown to improve the survival of patients with triple negative BC. This narrative review summarizes the studies supporting the use of immunotherapy in BC. Furthermore, the usefulness of…

    Tweet Tweets with this article
    • Ahead of new guidelines in process on PET in #breastcancer, proud to present this review: PET/CT in Patients with Breast Cancer Treated with Immunotherapy #PET https://t.co/NEV8WiU8gI

  • Mashup Score: 0

    Telix Pharmaceuticals has acquired Vienna, Austria-based Dedicaid, a spin-off of the Medical University Vienna, for $1.2 million.

    Tweet Tweets with this article
    • .@TelixPharma acquires Dedicaid, a spin-off of the Medical University Vienna, for $1.2M; Dedicaid's #CDS AI platform generates indication-specific apps from available datasets for use with #PET, img modalities; helps predict outcomes | #radiology #AI #MnA https://t.co/YTbSrmilLu

  • Mashup Score: 1

    In a video interview from the recent American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, Brian Chapin, MD, discussed emerging research that demonstrated the ability of the positron emission tomography (PET) agent 18F-rhPSMA-7.3 to diagnose distant M1 lesions prior to surgery for patients with intermediate to high-risk prostate cancer.

    Tweet Tweets with this article
    • Video: @ChapinMD discusses the #PET agent 18F-rhPSMA-7.3 and the diagnosis of distant M1 lesions in patients with #ProstateCancer. https://t.co/Dk8Labvmbb @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @SocietyAbdRad @UTSW_Radiology @OHSURadiology @UCSFimaging #radiology #RadRes https://t.co/j8XqakjXqZ